<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00036751</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02463</org_study_id>
    <secondary_id>SWOG-S0211</secondary_id>
    <secondary_id>U10CA032102</secondary_id>
    <secondary_id>CDR0000069319</secondary_id>
    <nct_id>NCT00036751</nct_id>
  </id_info>
  <brief_title>Imatinib Mesylate in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer</brief_title>
  <official_title>A Phase II Trial Of STI571 For The Treatment Of Platinum And Taxane Refractory Stage III And IV Epithelial Ovarian Cancer And Primary Peritoneal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      Phase II trial to study the effectiveness of imatinib mesylate in treating patients who have&#xD;
      stage III or stage IV ovarian epithelial or primary peritoneal cancer that has not responded&#xD;
      to previous treatment. Imatinib mesylate may stop the growth of tumor cells by blocking the&#xD;
      enzymes necessary for cancer cell growth&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      I. Determine the response rates (confirmed, complete, and partial) in patients with platinum-&#xD;
      and taxane-refractory stage III or IV ovarian epithelial or primary peritoneal cancer treated&#xD;
      with imatinib mesylate.&#xD;
&#xD;
      II. Determine the toxicity of this drug in these patients. III. Correlate, preliminarily,&#xD;
      CD117 and platelet-derived growth factor receptor expression levels with response in patients&#xD;
      treated with this drug.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive oral imatinib mesylate once daily in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      Patients are followed every 3 months for 1 year, every 6 months for 2 years, and then&#xD;
      annually thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 20-40 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2002</start_date>
  <primary_completion_date type="Actual">August 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate (complete and partial confirmed response)</measure>
    <time_frame>Up to 3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity as assessed by NCI Common Toxicity Criteria version 2.0</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Primary Peritoneal Cavity Cancer</condition>
  <condition>Recurrent Ovarian Epithelial Cancer</condition>
  <condition>Stage III Ovarian Epithelial Cancer</condition>
  <condition>Stage IV Ovarian Epithelial Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment (imatinib mesylate)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral imatinib mesylate once daily in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>imatinib mesylate</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Treatment (imatinib mesylate)</arm_group_label>
    <other_name>CGP 57148</other_name>
    <other_name>Gleevec</other_name>
    <other_name>Glivec</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (imatinib mesylate)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed epithelial carcinoma of the ovary or primary peritoneal&#xD;
             serous papillary carcinoma&#xD;
&#xD;
               -  No mixed Mullerian tumors&#xD;
&#xD;
               -  No borderline ovarian tumors&#xD;
&#xD;
          -  Stage III or IV disease at time of diagnosis by surgical staging&#xD;
&#xD;
          -  Expression of KIT (CD117) and/or platelet-derived growth factor receptor by&#xD;
             immunohistochemistry&#xD;
&#xD;
          -  Relapsed within 6 months after completion of or progressed while receiving prior&#xD;
             frontline chemotherapy with a platinum (cisplatin or carboplatin) and a&#xD;
             taxane(paclitaxel or docetaxel) administered concurrently or sequentially&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
          -  Performance status - Zubrod 0-1&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin at least 9 g/dL (transfusion allowed)&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  SGOT or SGPT no greater than 2.5 times ULN&#xD;
&#xD;
          -  Creatinine no greater than 1.5 times ULN&#xD;
&#xD;
          -  No New York Heart Association class III or IV heart disease (e.g., congestive heart&#xD;
             failure or myocardial infarction within the past 2 months)&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective barrier contraception during and for 3 months&#xD;
             after study participation&#xD;
&#xD;
          -  No other malignancy within the past 5 years except adequately treated basal cell or&#xD;
             squamous cell skin cancer, carcinoma in situ of the cervix, or other adequately&#xD;
             treated stage I or II cancer in complete remission&#xD;
&#xD;
          -  At least 28 days since prior biologic therapy&#xD;
&#xD;
          -  No concurrent anticancer biologic therapy&#xD;
&#xD;
          -  No concurrent cytokines (e.g., filgrastim [G-CSF] or sargramostim [GM-CSF])&#xD;
&#xD;
          -  At least 28 days since prior chemotherapy&#xD;
&#xD;
          -  No more than 3 prior chemotherapy regimens in addition to frontline chemotherapy&#xD;
&#xD;
               -  Retreatment with a platinum agent or with the same taxane as in the frontline&#xD;
                  regimen is not counted as an additional regimen&#xD;
&#xD;
          -  No concurrent chemotherapy&#xD;
&#xD;
          -  Prior hormonal therapy allowed&#xD;
&#xD;
          -  Recovered from prior radiotherapy&#xD;
&#xD;
          -  No prior radiotherapy to more than 25% of bone marrow&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
          -  Prior surgical debulking allowed for relapsed disease if measurable disease remains&#xD;
             after surgery&#xD;
&#xD;
          -  At least 14 days since prior major surgery&#xD;
&#xD;
          -  Recovered from all prior surgery&#xD;
&#xD;
          -  At least 28 days since prior investigational drugs&#xD;
&#xD;
          -  No concurrent therapeutic doses of warfarin for anticoagulation (heparin or mini-dose&#xD;
             warfarin (1 mg/day) allowed)&#xD;
&#xD;
          -  No other concurrent anticancer agents&#xD;
&#xD;
          -  No other concurrent investigational drugs&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Alberts</last_name>
    <role>Principal Investigator</role>
    <affiliation>Southwest Oncology Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Southwest Oncology Group (SWOG) Research Base</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78245</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>May 13, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>January 23, 2013</last_update_submitted>
  <last_update_submitted_qc>January 23, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imatinib Mesylate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

